Compare FCUV & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCUV | TCRT |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.8M |
| IPO Year | 2013 | 2025 |
| Metric | FCUV | TCRT |
|---|---|---|
| Price | $2.89 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 12.8M |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | N/A | ★ N/A |
| Revenue | $255,023.00 | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.13 | $0.72 |
| 52 Week High | $23.00 | $4.50 |
| Indicator | FCUV | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 47.57 |
| Support Level | $2.56 | $1.02 |
| Resistance Level | $3.24 | $2.02 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 42.42 | 7.48 |
Focus Universal Inc focuses on commercializing universal smart technology and financial reporting software. It plans to utilize its universal smart technology for smart meters and automation systems, which will be incorporated into IoT devices. The company has developed the five proprietary platform technologies: device on a chip; universal smart instrumentation platform (USIP); 5G ultra-narrowband technology; ultra-narrowband power line communication (PLC) technology; and its financial reporting software. The company consists of two segments: LED and IoT Installation Services, and SEC Financial Software segment. It derives the majority of the revenue from LED and IoT Installation Services segment which handles LED and IoT installation and management business.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.